Regulating Nanomedicine – Can the FDA handle it

 Raj Bawa
Description: Evidence continues to mount that many nanoproducts inherently posses novel size-based properties and toxicity profiles. Yet, there is no specific law or mechanism for oversight of nanomedicine and the FDA continues to treat nanoproducts as substantially equivalent (“bioequivalent”) to their bulk counterparts.
Views: 11625
Domain: Medical
Category: Biotech/Pharma
Maxims of Tech: Rules of Engagement for a Fast Changing Environment
Regulating Nanomedicine � Can the FDA handle it?
Raj Bawa**1, MS, PhD **Patent Agent, Bawa Biotechnology Consulting LLC, Ashburn, Virginia, USA; Adjunct Associate Professor, Biology Department, Rensselaer Polytechnic Institute, Troy, New York, USA; and Founding Director, American Society for Nanomedicine, Ashburn, Virginia, USA. Abstract There is enormous excitement and expec ... See more
Raj Bawa
29 March, 2011
Raj Bawa
18 November, 2010

The carbon nanotube patent

Carbon nanotubes (CNTs) have extraordinary properties that make them promising candidates for a wide variety of potential biomedical applications, including new therapeutics, dru

Raj Bawa
15 May, 2010